CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Update

CRISPR Therapeutics AG (NASDAQ:CRSP) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 19,100,000 shares, a growth of 5.4% from the December 31st total of 18,120,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the short-interest ratio is currently 11.4 days.

CRISPR Therapeutics Stock Down 1.1 %

CRISPR Therapeutics stock opened at $41.59 on Monday. The firm has a 50 day moving average price of $43.76 and a 200-day moving average price of $47.07. The company has a market capitalization of $3.55 billion, a P/E ratio of -14.70 and a beta of 1.68. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the firm earned ($1.41) EPS. Equities analysts expect that CRISPR Therapeutics will post -5.1 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Barclays cut their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, January 14th. Chardan Capital restated a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Finally, JMP Securities restated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $78.38.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics in the 3rd quarter valued at $43,000. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the 4th quarter valued at $39,000. Western Pacific Wealth Management LP boosted its holdings in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Finally, Eastern Bank bought a new position in CRISPR Therapeutics in the 3rd quarter valued at $70,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.